icon star paper   COVID-19  
Back grey_arrow_rt.gif
 
 
PrEP at CROI 2020
 
 
  CROI: HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial (04/09/20)
 
CROI: ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES (04/08/20)
 
Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
 
IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS (03/16/20)
 
DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
 
DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
 
WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
 
FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
 
F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - (03/11/20)
 
CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI - (04/04/20)

 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org